版本:
中国

BRIEF-U.S. FDA approves new combination treatment for acute myeloid leukemia

April 28 U.S. Food and Drug Administration :

* FDA approves new combination treatment for acute myeloid leukemia

* Says granted approval of Rydapt to Novartis Pharmaceuticals Corporation

* Approved Rydapt for treatment of adult patients with newly diagnosed acute myeloid leukemia with genetic mutation FLT3, in combination with chemotherapy

* Rydapt was also approved for adults with certain types of rare blood disorders

* Rydapt is approved for use with a companion diagnostic, LeukoStrat CDx FLT3 mutation assay

* Granted approval of LeukoStrat CDx FLT3 mutation assay to Invivoscribe Technologies Inc Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐